Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alberta Cancer Board |
---|---|
Information provided by: | Alberta Cancer Board |
ClinicalTrials.gov Identifier: | NCT00705094 |
For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.
Condition |
---|
Testicular Cancer Seminoma Non-Seminomatous |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients |
Estimated Enrollment: | 30 |
Study Start Date: | September 2008 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
Testicular cancer patients who have received surgery and are scheduled for surveillance
|
2
Testicular cancer patients who have received surgery and are scheduled for chemotherapy
|
The aim of this pilot study is to examine global and regional LV systolic and diastolic function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
testicular cancer patients who have recieved surgery and are scheduled for either chemotherapy or surveillance
Inclusion Criteria:
Exclusion Criteria:
Contact: Edith Pituskin, RN, PhD Student | (780) 432 - 8792 | pituskin@ualberta.ca |
Canada, Alberta | |
Cross Cancer Institute | Recruiting |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca | |
Principal Investigator: Mark Haykowsky, PhD |
Principal Investigator: | Mark Haykowsky, PhD | University of Alberta |
Responsible Party: | University of Alberta ( Mark Haykowsky, PhD ) |
Study ID Numbers: | GU-24167 |
Study First Received: | June 23, 2008 |
Last Updated: | January 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00705094 |
Health Authority: | Canada: Canadian Institutes of Health Research |
cardiovascular risk factors cardiac function VO2peak Chemotherapy |
Genital Neoplasms, Male Gonadal Disorders Neoplasms, Germ Cell and Embryonal Testicular Diseases Endocrine System Diseases Seminoma |
Testicular cancer Urogenital Neoplasms Endocrinopathy Testicular Neoplasms Genital Diseases, Male Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Germinoma |